[go: up one dir, main page]

WO1996026273A1 - Polypeptides tires de l'urinastatine presentant une activite d'inhibition calcique et leur utilisation pour retarder les accouchements prematures - Google Patents

Polypeptides tires de l'urinastatine presentant une activite d'inhibition calcique et leur utilisation pour retarder les accouchements prematures Download PDF

Info

Publication number
WO1996026273A1
WO1996026273A1 PCT/US1996/002018 US9602018W WO9626273A1 WO 1996026273 A1 WO1996026273 A1 WO 1996026273A1 US 9602018 W US9602018 W US 9602018W WO 9626273 A1 WO9626273 A1 WO 9626273A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
administering
inhibiting activity
urinastatin
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/002018
Other languages
English (en)
Inventor
Toshihiko Terao
Naohiro Kanayama
David Casal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adeza Biomedical Corp
Original Assignee
Adeza Biomedical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adeza Biomedical Corp filed Critical Adeza Biomedical Corp
Priority to AU48680/96A priority Critical patent/AU4868096A/en
Publication of WO1996026273A1 publication Critical patent/WO1996026273A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Figure 2 shows a tabular summary of the data for pregnant women undergoing treatment according to Example 2.
  • Figure 13 shows the effect of various UTI- derived polypeptides on [Ca 2+ ] i .
  • the present invention provides polypeptides having calcium channel blocking activity.
  • the invention also provides methods for diagnosing and treating a pregnant female with impending premature delivery, with the treatment using the polypeptides.
  • Recombinant host cells refer to cells which can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
  • An ELISA test of this type may be performed as follows.
  • the mucosal sample to be tested is obtained from the cervix or the posterior fornix of the vagina on a swab.
  • the swab is placed in buffer, in which the mucosal sample is diluted.
  • the concentration of fetal fibronectin is measured with an ELISA test (Fetal Fibronectin Immunoassay, Adeza Biomedical, Sunnyvale, CA) .
  • This assay utilizes a monoclonal antibody specific for the oncofetal antigen, followed by a goat anti-human plasma fibronectin IgG conjugated to alkaline phosphatase and a phenolphthalein monophosphate substrate.
  • UTI The effects of synthetic peptides of UTI on [Ca 2+ ] i of neutrophils were investigated.
  • the structure of UTI is shown in Fig. 1.
  • the polypeptide RAF (92- 94) resulted in 70% inhibition of the increment of cytosolic free Ca 2+ .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention décrit des polypeptides tirés de l'urinastatine présentant une activité d'inhibition calcique et dépourvus d'activité inhibitrice de l'élastase ainsi que d'activité inhibitrice de plasmine/cytokine/trypsine. L'invention décrit également des séquences polynucléotidiques codant ces polypeptides ainsi que des vecteurs contenant lesdites séquences polynucléotidiques et des cellules hôtes transformées en ces vecteurs. L'invention décrit encore un procédé pour établir un diagnostic et traiter une femme enceinte risquant un accouchement prématuré imminent. Ledit procédé consiste à administrer à la femme un polypeptide tiré de l'urinastatine présentant une activité d'inhibition calcique et dépourvu d'activité inhibitrice de l'élastase ainsi que d'activité inhibitrice de plasmine/cytokine/trypsine, ou un polypeptide tiré de l'urinastatine présentant une activité d'inhibition calcique et une activité inhibitrice de plasmine/cytokine/trypsine, mais dépourvu d'activité inhibitrice de l'élastase. L'invention décrit aussi une composition pharmaceutique de ces polypeptides ainsi qu'un antibiotique.
PCT/US1996/002018 1995-02-23 1996-02-13 Polypeptides tires de l'urinastatine presentant une activite d'inhibition calcique et leur utilisation pour retarder les accouchements prematures Ceased WO1996026273A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48680/96A AU4868096A (en) 1995-02-23 1996-02-13 Polypeptides derived from urinastatin having calcium channel blocking activity and their use to delay premature delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39431895A 1995-02-23 1995-02-23
US08/394,318 1995-02-23

Publications (1)

Publication Number Publication Date
WO1996026273A1 true WO1996026273A1 (fr) 1996-08-29

Family

ID=23558430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002018 Ceased WO1996026273A1 (fr) 1995-02-23 1996-02-13 Polypeptides tires de l'urinastatine presentant une activite d'inhibition calcique et leur utilisation pour retarder les accouchements prematures

Country Status (2)

Country Link
AU (1) AU4868096A (fr)
WO (1) WO1996026273A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7228295B2 (en) 1997-08-14 2007-06-05 Adeza Biomedical Corporation Methods for selecting, developing and improving diagnostic tests for pregnancy-related conditions
US7270970B2 (en) 1998-02-03 2007-09-18 Adeza Biomedical Corporation Point of care diagnostic systems
WO2020106881A1 (fr) * 2018-11-20 2020-05-28 Diamedica Inc. Polypeptides d'ulinastatine modifiés
CN114525247A (zh) * 2022-03-14 2022-05-24 吉林壹众生物科技有限公司 一种提高干细胞细胞因子产量的方法
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401508A2 (fr) * 1989-05-13 1990-12-12 Bayer Ag Inhibiteurs de protéinase, leur procédé de préparation ainsi que compositions pharmaceutiques les contenant
EP0486001A1 (fr) * 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Fragments recombinants de l'inhibiteur urinaire de la trypsine et composition pharmaceutique
EP0543240A1 (fr) * 1991-11-08 1993-05-26 Mochida Pharmaceutical Co., Ltd. Fragments recombinants d'un mutant de l'inhibiteur de trypsine d'origine urinaire et compositions pharmaceutiques
JPH05308988A (ja) * 1992-05-12 1993-11-22 Mochida Pharmaceut Co Ltd 新規ポリペプチド、新規ｄｎａ、新規ベクター、新規形質転換体、新規医薬組成物、および新規ポリペプチドの製造方法
EP0624644A1 (fr) * 1993-05-01 1994-11-17 Mochida Pharmaceutical Co., Ltd. Fragment d'ADN, vecteur contenant ce fragment d'ADN, transformant transformé avec le vecteur et procédé de production de protéine par utilisation du vecteur
WO1995012406A1 (fr) * 1993-11-04 1995-05-11 Adeza Biomedical Utilisation de composes semblables a l'urinastatine pour empecher les accouchements prematures

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401508A2 (fr) * 1989-05-13 1990-12-12 Bayer Ag Inhibiteurs de protéinase, leur procédé de préparation ainsi que compositions pharmaceutiques les contenant
EP0486001A1 (fr) * 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Fragments recombinants de l'inhibiteur urinaire de la trypsine et composition pharmaceutique
EP0543240A1 (fr) * 1991-11-08 1993-05-26 Mochida Pharmaceutical Co., Ltd. Fragments recombinants d'un mutant de l'inhibiteur de trypsine d'origine urinaire et compositions pharmaceutiques
JPH05308988A (ja) * 1992-05-12 1993-11-22 Mochida Pharmaceut Co Ltd 新規ポリペプチド、新規ｄｎａ、新規ベクター、新規形質転換体、新規医薬組成物、および新規ポリペプチドの製造方法
EP0624644A1 (fr) * 1993-05-01 1994-11-17 Mochida Pharmaceutical Co., Ltd. Fragment d'ADN, vecteur contenant ce fragment d'ADN, transformant transformé avec le vecteur et procédé de production de protéine par utilisation du vecteur
WO1995012406A1 (fr) * 1993-11-04 1995-05-11 Adeza Biomedical Utilisation de composes semblables a l'urinastatine pour empecher les accouchements prematures

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1994 (1994-12-01), N. KANAYAMA: "Intrauterine defensive mechanism of amniotic fluid and fetal membranes", XP002005590 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 1992 (1992-09-01), N. KANAYAMA ET AL.: "The effect of granulocyte elastase inhibitor (urinastatin) vaginal suppository on patients with imminent premature delivery", XP002005699 *
KANAYAMA N ET AL: "Urinary trypsin inhibitor suppresses premature cervical ripening.", EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY 60 (2). 1995. 181-186. ISSN: 0301-2115, June 1995 (1995-06-01), XP000572784 *
NIPPON SANKA FUJINKA GAKKAI ZASSHI. ACTA OBSTETRICA ET GYNAECOLOGICA JAPONICA, vol. 44, no. 4, April 1992 (1992-04-01), pages 477 - 482 *
NIPPON SANKA FUJINKA GAKKAI ZASSHI. ACTA OBSTRETRICA ET GYNAECOLOGICA JAPONICA, vol. 46, no. 8, August 1994 (1994-08-01), pages 673 - 765 *
PATENT ABSTRACTS OF JAPAN vol. 18, no. 114 (C - 1171) 24 February 1994 (1994-02-24) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7228295B2 (en) 1997-08-14 2007-06-05 Adeza Biomedical Corporation Methods for selecting, developing and improving diagnostic tests for pregnancy-related conditions
US7270970B2 (en) 1998-02-03 2007-09-18 Adeza Biomedical Corporation Point of care diagnostic systems
WO2020106881A1 (fr) * 2018-11-20 2020-05-28 Diamedica Inc. Polypeptides d'ulinastatine modifiés
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides
CN114525247A (zh) * 2022-03-14 2022-05-24 吉林壹众生物科技有限公司 一种提高干细胞细胞因子产量的方法

Also Published As

Publication number Publication date
AU4868096A (en) 1996-09-11

Similar Documents

Publication Publication Date Title
Kirchhoff et al. Molecular cloning and characterization of HE1, a major secretory protein of the human epididymis
Xie et al. A novel glycoprotein of the aspartic proteinase gene family expressed in bovine placental trophectoderm
Kirchhoff et al. Function of human epididymal proteins in sperm maturation
Gipson et al. Mucin genes expressed by human female reproductive tract epithelia
US5650394A (en) Use of urinastatin-like compounds to prevent premature delivery
Tomasetto et al. Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide
Van Duin et al. Recombinant human zona pellucida protein ZP3 produced by Chinese hamster ovary cells induces the human sperm acrosome reaction and promotes sperm-egg fusion
Simpson et al. Transforming growth factor β expression in human placenta and placental bed during early pregnancy
US20230027709A1 (en) Compositions and methods for regulating sas1r
Osterhoff et al. Molecular cloning and characterization of a novel human sperm antigen (HE2) specifically expressed in the proximal epididymis
JP2014193920A (ja) 子癇前症または子癇の診断方法および治療方法
JP2001513626A (ja) 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
Garczynski et al. Molecular characterization of a ribonucleic acid transcript that is highly up-regulated at the time of ovulation in the brook trout (Salvelinus fontinalis) ovary
TAYLOR et al. Preeclamptic sera stimulate increased platelet‐derived growth factor mRNA and protein expression by cultured human endothelial cells
US7091322B2 (en) Human endometrial specific steroid-binding factor I, II, and III
KR101515700B1 (ko) Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법
JPH08507530A (ja) トランスフォーミング成長因子βによる受胎能調節
Nichols et al. Expression of a membrane form of the pregnancy-associated protein TJ6 on lymphocytes
WO1996026273A1 (fr) Polypeptides tires de l'urinastatine presentant une activite d'inhibition calcique et leur utilisation pour retarder les accouchements prematures
CN108866181A (zh) Mboat1基因在子痫前期中的应用
Bell et al. Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes
Curtis et al. The expression of parathyroid hormone-related protein mRNA and immunoreactive protein in human amnion and choriodecidua is increased at term compared with preterm gestation
US20040014664A1 (en) Methods and compositions for inhibiting angiogenesis
Cavallini et al. Lithostathine messenger RNA expression in different types of chronic pancreatitis
Xavier et al. Co-expression of the proto-oncogene FOS (c-fos) and an embryonic interferon (ovine trophoblastin) by sheep conceptuses during implantation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase